Skip to main content

Ibane Abasolo Olaortua

I am a researcher, head of the Drug Delivery & Targeting (DDT) group and a member of the Clinical Biochemistry Service. Our research is aimed at improving the treatment of various diseases through the use of nanoparticles of natural or synthetic origin that selectively deliver treatments to the cells that need them. I am also a member of the Department of Biochemistry and Molecular Biology of the Autonomous University of Barcelona and I participate in the VHIR Master's Degree in Translational Biomedicine where I coordinate the internship module.

Institutions of which they are part

Main researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca
Biologist
Bioquímica
Cross-departmental services

Ibane Abasolo Olaortua

Institutions of which they are part

Main researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca
Biologist
Bioquímica
Cross-departmental services

I am a researcher, head of the Drug Delivery & Targeting (DDT) group and a member of the Clinical Biochemistry Service. Our research is aimed at improving the treatment of various diseases through the use of nanoparticles of natural or synthetic origin that selectively deliver treatments to the cells that need them. I am also a member of the Department of Biochemistry and Molecular Biology of the Autonomous University of Barcelona and I participate in the VHIR Master's Degree in Translational Biomedicine where I coordinate the internship module.

I graduated in Biochemistry and Biology at the University of Navarra. During my doctorate in the laboratories of Dr. Alfonso Calvo (CIMA, Pamplona) and Prof. Zhou Wang (Northwestern University, Chicago, USA), I studied the role of a peptide hormone, adrenomedullin, in cancer. Later, I continued my postdoctoral training in the group of Prof. F.X. Real (IMIM, Barcelona), where I acquired extensive experience in experimental mouse models, from the generation of transgenic models to their molecular characterization, an experience that I completed with a specialization in molecular imaging techniques at the IAT-PRBB.
Since 2007, I have been working at Vall d'Hebron, where I started as a post-doctoral researcher and head of the technology platform called Functional Validation & Preclinical Research (FVPR)-U20 ICTS. Since 2021 I am also the leader of the Drug Delivery & Targeting group at VHIR and at the CIBER for Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN).
My research, and that of my group, seeks to improve the treatment of different diseases through the use of nanoparticles and hydrogels. These systems are specifically designed to protect the therapeutic agent and cause it to be released where and when it is needed. Noteworthy, we work at all steps of the preclinical development, from the design of the nanomaterial, to its synthesis, characterization and testing in experimental models of the disease.
I am currently leading two European projects (SafeNMT and Mimic-key) and two Spanish projects (PI21/00930 and NanoDireCT), focused on the treatment of cancer (breast, pancreas and prostate) and lysosomal storage diseases (Fabry, Sanfilippo and pycnodysostosis).

Research lines

Rapid and efficient in vivo evaluation of synthetic and natural nanoparticles by means of devoted animal models and non-invasive imaging techniques

IP: Ibane Abasolo Olaortua

Obtenció i us de vesícules extracel·lulars com vehicles per proteïnes i biomolècules

IP: Ibane Abasolo Olaortua

Study of the molecular and cellular bases of the intercommunication between tumor cells and their environment as a way to better understand the disease progression in cancer

IP: Ibane Abasolo Olaortua

Design, synthesis and characterization of synthetic nanotechnological systems, especially polymeric micelles and hydrogels with which to improve the therapeutic window of drugs, nucleic acids and advanced therapies

IP: Ibane Abasolo Olaortua

Projects

MycoMatrix: engineering of a recombinant live biotherapeutic to normalise tumour extracellular matrix in KRAS-driven Non-Small Cell Lung Cancer

IP: Ibane Abasolo Olaortua
Collaborators: Joaquin Seras Franzoso, Fernanda Raquel Da Silva Andrade
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 333099
Reference: CPP2022-009780
Duration: 01/07/2023 - 30/06/2026

Ministerio de Ciencia

TACTIC: Explorando soluciones a los retos de salud mediante ciencia disruptiva, terapias avanzadas y medicina de sistemas

IP: Begoña Benito Villabriga
Collaborators: Carmen Escudero Iriarte, Laia Ventura i Expósito, Susana Otero Romero, Ibane Abasolo Olaortua, Ignacio Ferreira González, José Antonio Barrabés Riu, Carlos Nos Llopis, Pablo Velasco Puyó, Jose Fernando Rodríguez Palomares, María Rosario Pérez- Torres Lobato, Sunny Malhotra Sareen, Perez Dueñas, Belen, Jaume Sastre Garriga, Joan López Hellin, Antonia Sambola Ayala, Jordi Rio Izquierdo, Nuria Rivas Gandara, Jordi Perez Rodon, Aroa Soriano Fernández, Manuel Comabella Lopez, Antonio Rodríguez Sinovas, Gisela Teixido Tura, Antonia Pijuan Domenech, Roser Ferrer Costa, Joaquin Seras Franzoso, Carmen Tur Gomez, Maria Cristina Díaz de Heredia Rubio, Laia Yañez Bisbe, Julia German Cortes, Maria Jose Pérez García, Miguel Segura Ginard, Diego Baranda Martínez-Abasca, Cristina Auger Acosta, Neus Bellera Gotarda, Herena Eixarch Ahufinger, M Mar Mañu Pereira, Deborah Pareto Onghena, Lorena Valero Arrese, Aitor Uribarri Gonzalez, Jordi Bañeras Rius, Alex Rovira Cañellas, Mar Tintore Subirana, Bruno García del Blanco, Maria Teresa Salcedo Allende, Marisol Ruiz Meana, Ana Belén Méndez Fernández, Xavier Montalban Gairín, Simon Schwartz Navarro, Anna Llort Sales, Carmen Espejo Ruiz, Raquel Hladun Alvaro, Angels Alcina Mila, Sandra Mancilla Zamora, Zamira Vanessa Diaz Riascos, Ana Zabalza de Torres, Ariadna Boloix Amenós, Marc Miquel Moltó Abad, Javier Inserte Igual, Elizabeth Pando Rau, Gabriela Guillén Burrieza, Cazurro Gutierrez, Ana Laura, Gómez Andrés, David, Alvaro Cobo Calvo, Alvaro Calabuig Goena, Joaquin Castillo Justribo, Lydia Dux-Santoy Hurtado, Lucas Moreno Martín-Retortillo, Andres Miguez Gonzalez, Josep Roma Castanyer, Laura Dos Subirá, Nicolás Miguel Fissolo, Maria Nazarena Pizzi, Tian Tian, Fernanda Raquel Da Silva Andrade, Diana Fernandes de Rafael, Andrea Guala
Funding agency: Instituto de Salud Carlos III
Funding: 2494527.53
Reference: FORT23/00034
Duration: 01/01/2024 - 31/12/2027

EVERETT: Engineered mesenchymal stromal cell Extracellular Vesicles for immunomodulatory biotherapy and Enzyme REplacemenT Therapy

IP: Ibane Abasolo Olaortua
Collaborators: -
Funding agency: Agence Nationale de la Recherche
Funding: 0.01
Reference: EVERETT_ANR-BIOPNSE2020
Duration: 01/11/2022 - 31/10/2025

EXOPROD - Vesículas extracelulares dirigidas, como sistemas de liberación de proteínas recombinantes

IP: Ibane Abasolo Olaortua
Collaborators: -
Funding agency: Fundación Innov. y Prosp. Salud en España - FIPSE
Funding: 30000
Reference: 3969-21
Duration: 07/04/2021 - 07/12/2021

Related news

Using computed tomography (CT), with or without contrast, it is possible to perform an accurate and safe detection of the disease without the need for biopsies and avoiding the limitations of other non-invasive diagnostic tools.

The European project, in which Vall d'Hebron participates, will favor personalized diagnosis and innovative therapeutic strategies in patients with the disease.

In total, different projects of six research groups will be promoted, focusing on precision medicine and advanced therapies.

Related professionals

Francina Munell Casadesus

Francina Munell Casadesus

Main researcher
Pediatric Neurology
Read more
Jorge Daniel Fernández Núñez

Jorge Daniel Fernández Núñez

Read more
Elida Teresa Mercado Santis

Elida Teresa Mercado Santis

Read more
Montserrat Perez Gonzalez

Montserrat Perez Gonzalez

Research technician
Clinical Pharmacology
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.